guanosine-5--o-(3-thiotriphosphate) and Hypotension

guanosine-5--o-(3-thiotriphosphate) has been researched along with Hypotension* in 2 studies

Other Studies

2 other study(ies) available for guanosine-5--o-(3-thiotriphosphate) and Hypotension

ArticleYear
Evidence for synergy between alpha(2)-adrenergic and nonadrenergic mechanisms in central blood pressure regulation.
    Circulation, 2002, Mar-05, Volume: 105, Issue:9

    Both alpha(2)-adrenergic and non--alpha(2)-adrenergic mechanisms seem to be involved in the hypotensive effect of imidazoline-like drugs. This study aimed at investigating how these 2 mechanisms work together to modify blood pressure (BP).. LNP 509, which appeared in this study to be devoid of alpha(2A)-adrenergic activity, was administered to anesthetized rabbits and wild-type (WT) mice into the cisterna magna and into the fourth ventricle, respectively. Mean arterial pressure decreased by a maximum of 46 +/- 4% and 16 +/- 2%, respectively. In D79N mice, which lack functional alpha(2A)-adrenergic receptors, LNP 509 also reduced mean arterial pressure by 17 +/- 2%. The hypotension induced by LNP 509 (100 microg/kg intracisternally) was prevented by S23757 (1 mg/kg intracisternally), an antagonist highly selective for I(1)-imidazoline binding sites (I(1)BS). A synergy between LNP 509 and the alpha(2)-adrenergic agonist alpha-methylnoradrenaline (alpha-MNA) was observed in rabbits (cisterna magna injection) and in WT mice (fourth ventricle injection) but not, as expected, in D79N mice. Similar to LNP 509 alone, rilmenidine (fourth ventricle injection), which binds both to alpha(2)-adrenergic receptors and to I(1)BS, decreased BP in D79N mice. In WT animals, rilmenidine had a significantly greater effect. Microinjections performed in rabbits showed that the synergism occurred at least in part in the nucleus reticularis lateralis of the brain stem.. These results demonstrate that a central imidazoline-sensitive, but non--alpha(2)-adrenergic, mechanism can modify BP by itself. This mechanism, which may involve I(1)BS, interacts synergistically with an alpha(2)-adrenergic mechanism to decrease BP.

    Topics: Adrenergic Agonists; Adrenergic alpha-Agonists; Animals; Antihypertensive Agents; Blood Pressure; Brain Stem; Cardiovascular System; Cyclopropanes; Drug Synergism; Guanosine 5'-O-(3-Thiotriphosphate); Hypotension; Imidazoles; Injections, Intraventricular; Mice; Mice, Transgenic; Microinjections; Nordefrin; Oxazoles; Pyrroles; Rabbits; Receptors, Adrenergic; Receptors, Adrenergic, alpha-2; Rilmenidine; Sympathetic Nervous System

2002
alpha 2A-adrenoceptors, not I1-imidazoline receptors, mediate the hypotensive effects of rilmenidine and moxonidine in conscious mice. In vivo and in vitro studies.
    Annals of the New York Academy of Sciences, 1999, Jun-21, Volume: 881

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Cell Line; Dogs; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Hypotension; Imidazoles; Imidazoline Receptors; In Vitro Techniques; Male; Mice; Mice, Inbred Strains; Muscle Contraction; Muscle, Smooth, Vascular; Norepinephrine; Oxazoles; Quinolizines; Receptors, Adrenergic, alpha-2; Receptors, Drug; Rilmenidine; Saphenous Vein; Transfection

1999